Clinical Trial Update: Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations [Phase 2]

View source ↗

Summary

This entry outlines a Phase 2 clinical trial testing olutasidenib in combination with a co-targeted therapy for relapsed or refractory IDH1-mutated myeloid mali…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia
• Myeloproliferative Neoplasm

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Targeted Therapy, IDH1-Mutated Malignancies | Phase 2 | Status: RECRUITING